tiprankstipranks
Trending News
More News >
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market

Prelude Therapeutics (PRLD) Income Statement

Compare
175 Followers

Prelude Therapeutics Income Statement

Last quarter (Q4 2025), Prelude Therapeutics's total revenue was $5.64M, an increase of 41.00% from the same quarter last year. In Q4, Prelude Therapeutics's net income was $-16.46M. See Prelude Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 12.14M$ 7.00M$ 0.00$ 0.00$ 0.00
Gross Profit
$ 10.43M$ 7.00M$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 115.00M$ 146.71M$ 132.28M$ 123.54M$ 113.73M
Depreciation and Amortization
$ 1.71M$ 1.77M$ 1.17M$ 1.32M$ 915.00K
EBITDA
$ -102.86M$ -137.94M$ -131.11M$ -122.22M$ -112.82M
Operating Income
$ -104.57M$ -139.71M$ -132.28M$ -123.54M$ -113.73M
Other Income/Expenses
$ 5.07M$ 12.54M$ 10.44M$ 8.10M$ 2.04M
Pretax Income
$ -99.50M$ -127.17M$ -121.83M$ -115.44M$ -111.69M
Net Income
$ -99.50M$ -127.17M$ -121.83M$ -115.44M$ -111.69M
Per Share Metrics
Basic EPS
$ -1.29$ -1.68$ -2.02$ -2.27$ -2.33
Diluted EPS
$ -1.29$ -1.68$ -2.02$ -2.27$ -2.33
Weighted Average Shares Outstanding
76.96M 75.81M 60.36M 47.37M 47.60M
Weighted Average Shares Outstanding (Diluted)
76.96M 75.81M 60.36M 47.37M 47.60M
Currency in USD

Prelude Therapeutics Earnings and Revenue History